Variables | Crude hazard ratio (95%CI) | Adjusted hazard ratio(95%CI) |
---|---|---|
Age | ||
15–24 | Reference | Reference |
25–34 | 0.85 (0.56 1.29) | 0.91 (0.60 1.39) |
35–44 | 0.81 (0.52 1.25) | 0.85 (0.54 1.32) |
≥ 45 | 0.76 (0.45 1.28) | 0.86 (0.50 1.47) |
Gender | ||
Female | Reference | Reference |
male | 1.10 (0.86 1.41) | 1.18 (0.91 1.53) |
BMI(kg/m2) | ||
< 18.5 | 1.26 (0.98 1.62) | 1.09 (0.83 1.42) |
18.5–24.99 | Reference | Reference |
> 25 | 0.67 (0.39 1.20) | 0.76 (0.44 1.33) |
CD4 count at switch | ||
≥ 100 cells/mm3 | Reference | Reference |
< 100 cells/mm3 | 0.82 (0.64 1.05) | 0.88 (0.68 1.14) |
Regimen modification | ||
Yes | Reference | Reference |
No | 1.65 (1.27 2.14) | 1.55 (1.18 2.04) |
ART adherence | ||
good | Reference | Reference |
Fair | 1.11 (0.78 1.59) | 1.12 (0.78 1.61) |
poor | 1.55 (1.18 2.03) | 1.40 (1.06 1.85) |
WHO clinical stage | ||
I | Reference | Reference |
II | 0.95 (0.59 1.53) | 0.84 (0.52 1.39) |
III | 0.78 (0.59 1.04) | 0.68 (0.50 0.91) |
IV | 1.44 (0.98 2.11) | 1.14 (0.75 1.73) |
Isoniazid Preventive Therapy (INH) given | ||
Yes | Reference | Reference |
No | 1.70 (1.25 2.32) | 1.68 (1.23 2.30) |
Functional status at switch | ||
Working | Reference | Reference |
Ambulatory | 1.45 (1.03 2.04) | 1.42 (0.97 2.07) |
bedridden | 1.99 (0.98 4.05) | 1.94 (0.93 4.05) |
Opportunistic Infections (OI) | ||
Yes | Reference | Reference |
No | 1.00 (0.62 1.62) | 0.98 (0.60 1.61) |
Second-line regimen | ||
ABC-ddI-LPV/r | Reference | Reference |
TDF-3TC-LPV/r | 1.59 (1.08 2.35) | 1.55 (1.03 2.32) |
AZT-3TC-LPV/r | 2.85(1.79 4.53) | 3.00 (1.86 4.85) |
Othersa | 1.89(1.28 2.82) | 1.77 (1.19 2.67) |